REN 1654

Drug Profile

REN 1654

Alternative Names: CPI 1189; REN 1189

Latest Information Update: 01 May 2007

Price : $50

At a glance

  • Originator Renovis
  • Class Analgesics; Neuroprotectants; Small molecules
  • Mechanism of Action Free radical scavengers; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dementia; Inflammatory bowel diseases; Postherpetic neuralgia; Sciatica

Most Recent Events

  • 25 Aug 2005 Discontinued - Phase-II for Sciatica in USA (PO)
  • 25 Aug 2005 Preclinical trials in Sciatica in USA (unspecified route)
  • 07 Mar 2005 Discontinued - Phase-II for Postherpetic neuralgia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top